Literature DB >> 3015200

Limited proteolysis of human von Willebrand factor by Staphylococcus aureus V-8 protease: isolation and partial characterization of a platelet-binding domain.

J P Girma, M W Chopek, K Titani, E W Davie.   

Abstract

Purified human von Willebrand factor (vWF) was digested with Staphylococcus aureus V-8 protease, and specific domains interacting with platelets were isolated and characterized. Amino acid sequence analysis and sodium dodecyl sulfate gel electrophoresis demonstrated that the digestion proceeded primarily by a single cleavage of the native 270K subunit between an internal Glu-Glu peptide bond. This produced an integral stepwise degradation of the multimers of vWF with a concomitant accumulation of bands with mobility similar to that of the smaller molecular weight vWF multimers. The immediate precursor of the final products contained equimolar amounts of 270K subunit and of two polypeptides (170K and 110K). The cleavage of the remaining 270K subunit converted vWF into two main fragments (fragments II and III). These fragments were isolated by ion exchange chromatography, characterized, and assayed for platelet binding in the presence of ristocetin. Fragment III is a dimer of 315K composed primarily of two chains of 170K. Amino acid sequence analysis indicated that it originated from the amino-terminal portion of the 270K subunit and contained 11% of the original ristocetin cofactor activity. Also, it binds to platelets at the same specific sites as native vWF and shows a platelet binding pattern similar to that of partially reduced vWF (500K). Fragment II is a dimer of 235K composed of two identical chains of 110K. Amino acid sequence analysis indicated that it originated from the carboxyl-terminal portion of the 270K subunit and lacked ristocetin cofactor activity. Also, it does not bind to platelets or inhibit the binding of 125I-vWF in the presence of ristocetin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015200     DOI: 10.1021/bi00359a013

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Allosteric activation of ADAMTS13 by von Willebrand factor.

Authors:  Joshua Muia; Jian Zhu; Garima Gupta; Sandra L Haberichter; Kenneth D Friedman; Hendrik B Feys; Louis Deforche; Karen Vanhoorelbeke; Lisa A Westfield; Robyn Roth; Niraj Harish Tolia; John E Heuser; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 2.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.

Authors:  R Schneppenheim; J Brassard; S Krey; U Budde; T J Kunicki; L Holmberg; J Ware; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

5.  A pH-regulated dimeric bouquet in the structure of von Willebrand factor.

Authors:  Yan-Feng Zhou; Edward T Eng; Noritaka Nishida; Chafen Lu; Thomas Walz; Timothy A Springer
Journal:  EMBO J       Date:  2011-08-19       Impact factor: 11.598

6.  Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor.

Authors:  B Samor; J C Michalski; C Mazurier; M Goudemand; P De Waard; J F Vliegenthart; G Strecker; J Montreuil
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

7.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

8.  Epitope mapping by cDNA expression of a monoclonal antibody which inhibits the binding of von Willebrand factor to platelet glycoprotein IIb/IIIa.

Authors:  G Piétu; A S Ribba; G Chérel; D Meyer
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

Review 9.  Acquired von Willebrand syndrome associated with left ventricular assist device.

Authors:  Angelo Nascimbene; Sriram Neelamegham; O H Frazier; Joel L Moake; Jing-Fei Dong
Journal:  Blood       Date:  2016-05-03       Impact factor: 22.113

10.  Purification and characterization of beta-structural domains of beta-lactoglobulin liberated by limited proteolysis.

Authors:  S X Chen; C C Hardin; H E Swaisgood
Journal:  J Protein Chem       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.